Loading
companiesCompany
Asher Biotherapeutics
Asher Bio engineers immune-stimulating molecules that switch on only one type of immune cell, such as killer T cells, so the drug is more potent against tumours and causes fewer side effects.
Overview
Asher Biotherapeutics builds cis-targeted immunotherapies: a cytokine fused to an antibody arm that binds a marker on the intended cell type, so the cytokine acts selectively rather than on every cell bearing its receptor. The lead programme AB248 is a CD8-targeted interleukin-2 in phase 1 for advanced solid tumours, alone and with pembrolizumab; a second programme targets regulatory T cells for autoimmune disease. The company was founded with Third Rock Ventures, went through YC, and has raised Series A and B rounds; amounts are not recorded here because no primary source was fetched.
Headquarters
South San Francisco, CA, US
Funding
All startupsGrowth stageYC S19
Investors
Type
Stage
Growth stage · Y Combinator Summer 2019
Website
Similar pages
- CompanyGranza Bio
Shares Y Combinator, Cytokines & engineered cytokines and the tag yc.
- CompanySynsoryBio
Shares Y Combinator, Cytokines & engineered cytokines and the tag yc.
- CompanyArpeggio Bio
Shares Y Combinator, Melanoma and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.